Stroke Trials Unit, University of Nottingham, Nottingham, UK.
J Neurol Neurosurg Psychiatry. 2013 Mar;84(3):342-7. doi: 10.1136/jnnp-2012-303396. Epub 2012 Oct 31.
Current evidence suggests that the time lag from the publication of randomised clinical trial results to changes in prescribing behaviour for drugs is gradually reducing. However, the effect of results of clinical trials of devices and non-pharmacological interventions on clinical practice is less clear.
Prospective data from the ongoing international 'Efficacy of Nitric Oxide Stroke' (ENOS) trial were analysed to assess the use of graduated compression stockings (GCS) for deep vein thrombus (DVT) prophylaxis in acute stroke patients before and after publication of the large 'Clots in Legs Or sTockings after Stroke' (CLOTS-1) trial.
Data on GCS use were available for 1971 patients with acute stroke enrolled into ENOS from February 2003 to April 2011; of these, 498 (25.3%) wore GCS. Prior to publication of CLOTS-1, GCS use was common (>50%) in the UK, Australasia and Canada but infrequent in Asia and the rest of Europe. After publication of CLOTS-1, use of GCS in the UK declined from 398/656 (61%) to 20/567 (4%) (p<0.001) but not elsewhere (eg, in Australasia (57% before publication vs 70% after publication, p=0.24, but based on small numbers). Practice change was apparent within 3 months of the study publication and was sustained thereafter. There was no change in DVT rates before and after CLOTS-1 (0.8% vs 1.0%).
GCS use declined dramatically following the reporting of the CLOTS-1 trial. The results support the notion that a neutral trial of a device can influence clinical practice rapidly, which is important with a widely used and moderately expensive (time and finance) intervention.
目前的证据表明,随机临床试验结果公布后,药物处方行为的改变时间逐渐缩短。然而,设备和非药物干预临床试验结果对临床实践的影响尚不清楚。
对正在进行的国际“一氧化氮卒中疗效”(ENOS)试验的前瞻性数据进行分析,以评估在大型“腿部血栓或袜子后的血栓(CLOTS-1)试验”公布后,急性卒中患者使用分级加压袜(GCS)预防深静脉血栓形成(DVT)的情况。
ENOS 试验从 2003 年 2 月至 2011 年 4 月共纳入 1971 例急性卒中患者,其中 498 例(25.3%)使用 GCS。在 CLOTS-1 公布之前,英国、澳大拉西亚和加拿大使用 GCS 的情况很常见(>50%),但在亚洲和欧洲其他地区则很少见。CLOTS-1 公布后,英国 GCS 的使用从 656 例中的 398 例(61%)下降到 567 例中的 20 例(4%)(p<0.001),但在其他地方则没有(例如,澳大拉西亚的使用情况从 57%降至 70%,p=0.24,但基于样本量较小)。研究发表后 3 个月内就出现了实践上的改变,此后一直持续。CLOTS-1 公布前后 DVT 发生率没有变化(0.8%和 1.0%)。
CLOTS-1 试验报告后,GCS 的使用急剧下降。结果支持了这样一种观点,即对设备的中立试验可以迅速影响临床实践,这对于一种广泛使用且价格适中(时间和财务)的干预措施非常重要。